Table 2.
The clinical information of 178 CMML patients classified as CMML-0, -1, and -2
| Variables | CMML-0 (n = 65) |
CMML-1 (n = 58) |
CMML-2 (n = 55) |
P value | 0 vs. 1 | 0 vs. 2 | 1 vs. 2 |
|---|---|---|---|---|---|---|---|
| Age in years; median (range) | 65 (24–86) | 62 (23–82) | 59 (17–90) | 0.085 | – | – | – |
| Sex (male); n (%) | 41 (63.1%) | 43 (73.1%) | 34 (61.8%) | 0.383 | – | – | – |
| Hemoglobin (g/L); median (range) | 89 (53–173) | 82 (38–153) | 84.0 (39–131) | 0.049 | 0.267 | 0.058 | 1.000 |
| WBC (×109/L); median (range) | 9.32 (1.38–158.9) | 12.79 (3.15–177.7) | 23.7 (1.22-323.66) | 0.007 | 1.000 | 0.007 | 0.068 |
| ANC (×109/L); median (range) | 4.66 (0.51–32) | 3.92 (0.45–20.62) | 6.35 (1.06–29.97) | 0.606 | – | – | – |
| AMC (×109/L); median (range) | 2.4 (1.11–6.5) | 2.43 (1.01–6.45) | 2.85 (1.01–16.32) | 0.600 | – | – | – |
| Platelets(×109/L); median (range) | 101 (11–977) | 66 (6-900) | 62 (3-610) | 0.015 | 0.046 | 0.037 | 1.000 |
| LDH (IU/ml); median (range) | 230.5 (120–1403) | 266 (152.4–623) | 352 (121.6–1298) | 0.046 | 1.000 | 0.097 | 0.136 |
| Cytogenetic risk groupa; n (%) | |||||||
| Low-risk | 55 (84.6%) | 38 (65.5%) | 36 (65.5%) | 0.023 | 0.014 | 0.015 | 0.994 |
| Intermediate-risk | 5 (7.7%) | 7 (12.1%) | 6 (10.9%) | 0.704 | – | – | – |
| High-risk | 5 (7.7%) | 13 (22.4%) | 13 (23.6%) | 0.034 | 0.021 | 0.015 | 0.877 |
| Splenomegaly; n (%) | 16 (28.6%) | 12 (26.1%) | 14 (30.4%) | 0.898 | – | – | – |
| Treatment strategy; n (%) | |||||||
| Best supportive care | 17 (51.5%) | 6 (23.1%) | 5 (15.2%) | 0.004 | 0.034 | 0.004 | 0.512 |
| HMAs ± chemotherapy/allo-HSCT | 16 (48.5%) | 20 (76.9%) | 28 (84.8%) | ||||